HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].

AbstractHISTORY:
A 65-year-old woman was admitted because of dyspnea at rest and peripheral edema due to scleroderma-associated pulmonary fibrosis and hypertension, as well as Raynaud's phenomenon.
DIAGNOSTIC FEATURES, TREATMENT AND COURSE:
She had a marked restrictive ventilatory disorder with severe impairment of diffusion capacity. Right heart catheterization demonstrated a mean pulmonary artery pressure of 50 mmHg. She was able to walk only 220 m. All usual methods of treatment failed to give satisfactory results so that sildenafil (phospherodiesterase type-5 |PDE-5| inhibitor; Viagra ((R)) was given, even though it is not licensed for this indications ("off-label", as a therapeutic attempt. This achieved definite reduction in pulmonary arterial pressure and significantly improved the clinical symptoms. In particular, it drastically reduced the level of atrial natriuretic peptide, an important prognostic marker in right heart failure. Sildenafil also significantly raised peripheral perfusion and the signs of Raynaud's syndrome.
CONCLUSION:
PDE-5 inhibitors are efficacious in scleroderma-associated pulmonary hypertension and may also provide a new option in the treatment of Raynaud's disease.
AuthorsS Rosenkranz, E Caglayan, F Diet, T Karasch, J Weihrauch, K Wassermann, E Erdmann
JournalDeutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 129 Issue 33 Pg. 1736-40 (Aug 13 2004) ISSN: 0012-0472 [Print] Germany
Vernacular TitleLangzeiteffekte von Sildenafil bei Sklerodermie-assoziierter pulmonaler Hypertonie und Raynaud-Syndrom.
PMID15295684 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Atrial Natriuretic Factor
  • Sildenafil Citrate
  • Phosphoric Diester Hydrolases
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human
Topics
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Aged
  • Atrial Natriuretic Factor (blood)
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Female
  • Fingers (blood supply)
  • Humans
  • Hypertension, Pulmonary (drug therapy, etiology)
  • Laser-Doppler Flowmetry
  • Phosphodiesterase Inhibitors (pharmacology, therapeutic use)
  • Phosphoric Diester Hydrolases (drug effects)
  • Piperazines (pharmacology, therapeutic use)
  • Prognosis
  • Pulmonary Wedge Pressure (drug effects)
  • Purines
  • Raynaud Disease (complications, drug therapy)
  • Regional Blood Flow (drug effects)
  • Scleroderma, Systemic (complications, drug therapy)
  • Sildenafil Citrate
  • Sulfones
  • Vasodilator Agents (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: